AUGUST 2022LIFE SCIENCES REVIEW6The COVID-19 pandemic has stimulated intense efforts to find effective therapeutics for all stages of the disease. Unfortunately, the scope, scientific rigour and clinical value of research activities undertaken worldwide have been difficult to gauge, especially amid the rapidly evolving landscape. From the very beginning of the search for effective preventive and therapeutic agents, the US Food and Drug Administration (FDA) have been committed to helping to identify and develop evidence-based therapeutics through well-designed clinical trials. It is critically important to protect patients from inefficacious or unsafe drugs while advancing those evidence-based efforts efficiently -- without duplication or otherwise wasting resources -- to bring effective interventions to patients.The spike in infections led to a steep increase in the number of clinical trials conducted to treat COVID-19, with most leading pharmaceutical, biotechnology and healthcare companies working towards producing drugs and vaccines. A market intelligence report estimates that the global COVID-19 therapeutics market will reach USD25.6bn in 2030 owing to the increase in the number of drug approvals and rising cases of COVID-19 and patient awareness.In a perfect world the goal is to develop a drug that will go after a single target (a protein, enzyme, DNA/RNA, etc. that will undergo a specific interaction with chemicals or biological drugs) that is linked to a disease. To get FDA approval new drugs have to be proven better than existing ones. Most of the low-hanging fruit of easy drugs to develop are already on the market. Unfortunately most diseases don't work that simply. There are a few diseases that do, (i.e. insulin and diabetes, Gleevec -Philadelphia Chromosome and chronic myeloid leukemia), but most small molecule drugs rarely act on a single target (target-based therapy in oncology being the bright spot.)The annual list of companies is selected by a panel of experts and members of Life Science Review Magazine's editorial board to recognize and promote technology entrepreneurship.Let us know your thoughts.EDITORIALThe Changing State of TherapeuticsCopyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com AUGUST - 29 - 2022, Vol 03, Issue - 19 (ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasCatalina Joseph Clara MatthewVisualizersRonald DonovanDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsSalesStephen Thomassales@lifesciencesreview.comVictor Cruz
< Page 5 | Page 7 >